Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.

01/16
2019

What happens when the doctor blames you for your own cancer?

How bias in the medical community hurts lung cancer patients. from The Washington Post Not long ago, I was working in a busy teaching hospital’s intensive-care unit, poring over EKGs, examining X-rays and reviewing medication orders. I re…

01/2
2019

Patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis

from EurekAlert University of Colorado Study Patients now living a median 6.8 years: According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between the years 1995 and 2001 had 15 percent chan…

01/2
2019

Lung Cancer Deaths are 28 Percent Lower in California

From UC San Diego Health State’s long-term, aggressive tobacco control programs cited as primary reason Early adoption of tobacco control efforts in California led to fewer people ever smoking, reduced the amount used by those who do smok…

01/2
2019

First-Line Immunotherapy Combo Fails to Improve Survival in Lung Cancer Trial

From Specialty Pharmacy Times Clinical Trial results: First-line immunotherapy combo fails: New study shows that first-line immunotherapy that uses durvalumab (Imfinzi, AstraZeneca) or the combination of durvalumab and tremelimumab failed t…

12/8
2018

FDA Approves Atezolizumab Combination

from Business Wire FDA Approves Atezolizumab in Combination Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approvedatezolizumab (Tecentriq®), in combination with Avastin® (bevac…

12/8
2018

Policy changes needed for access to lung cancer treatments

from The Hill Advances in Lung Cancer Treatment Advances in treatment have completely transformed the way that Americans are living with lung cancer, something that was unthinkable even ten years ago. Since 2015, the U.S. Food and Drug Ad…

12/5
2018

New DNA sequencing test credited with saving his life

from The Boston Globe I was only given months to live four years ago . . . I am still thriving John White, a retired North Attleborough bioengineer, was diagnosed in early 2015 with aggressive prostate cancer. It had spread to his bladder a…

10/23
2018

Personalized Medicine for NTRK Fusion-Positive Solid Tumors

From Market Watch: Personalized Medicine Entrectinib Shrank Tumors in People with NTRK Fusion-Positive Solid Tumors Entrectinib showed response irrespective of tumor type or spread to the central nervous system. Data will be submitted to …

10/17
2018

Women with lung cancer live longer than men

From Helio: Women with newly diagnosed stage I to stage III non-small cell lung cancer (NSCLC) appeared to have longer overall survival than their male counterparts, according to results of a trial presented at International Association …

10/17
2018

After Decades, New Standard of Care in Small Cell Lung Cancer

From Medscape: For the first time in decades, overall survival has been shown to improve in patients with extensive-stage small cell lung cancer (ES-SCLC) when concurrent immunotherapy is added to standard chemotherapy in the first-line set…

Research is imperative to improve treatment and management of all diseases and that’s particularly true of lung cancer. It’s creation of new knowledge, it’s discovery. It’s how we learn how to improve management of symptoms, to improve survival. ~Dr. David Johnson